应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
RNA Atrium Therapeutics
休市中 09-11 16:00:00 EDT
10.36
+0.01
+0.10%
盘后
10.20
-0.16
-1.54%
19:30 EDT
最高
10.41
最低
10.00
成交量
24.75万
今开
10.37
昨收
10.35
日振幅
3.92%
总市值
1.77亿
流通市值
1.63亿
总股本
1,711万
成交额
253.97万
换手率
1.57%
流通股本
1,572万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
AI辅助设计出新型RNA转运蛋白
格隆汇 · 09-08
AI辅助设计出新型RNA转运蛋白
奥博与贝恩资本加持，RNA新贵Adarx递交美股上市申请
智通财经 · 09-05
奥博与贝恩资本加持，RNA新贵Adarx递交美股上市申请
RNA疗法再迎突破！名古屋大学教授：新技术有望让药物作用时间更长
每日经济新闻 · 08-27
RNA疗法再迎突破！名古屋大学教授：新技术有望让药物作用时间更长
日本名古屋大学与富士胶片公司合作开发出一种新型脂质纳米颗粒（LNP），首次将带帽的环状RNA（Cap-cirRNA）高效
智通财经 · 08-23
日本名古屋大学与富士胶片公司合作开发出一种新型脂质纳米颗粒（LNP），首次将带帽的环状RNA（Cap-cirRNA）高效
Atrium Therapeutics 获资格：研发里程碑可高达13.5亿美元，商业里程碑达8.25亿美元，另享阶梯式版税
美股速递 · 08-13
Atrium Therapeutics 获资格：研发里程碑可高达13.5亿美元，商业里程碑达8.25亿美元，另享阶梯式版税
Atrium Therapeutics 获施贵宝1500万美元里程碑付款，源于全球心血管合作
美股速递 · 08-13
Atrium Therapeutics 获施贵宝1500万美元里程碑付款，源于全球心血管合作
Atrium Therapeutics（RNA）获施贵宝全额资助，未来开发与商业化活动全面启动
美股速递 · 08-13
Atrium Therapeutics（RNA）获施贵宝全额资助，未来开发与商业化活动全面启动
石药集团(01093)：SYS 6037注射液(猴痘m RNA疫苗)在美国获临床试验批准
智通财经 · 08-10
石药集团(01093)：SYS 6037注射液(猴痘m RNA疫苗)在美国获临床试验批准
Atrium Therapeutics宣布FDA批准Atr 1072用于治疗Prkag2综合征的研究性新药申请
美股速递 · 07-14
Atrium Therapeutics宣布FDA批准Atr 1072用于治疗Prkag2综合征的研究性新药申请
Atrium Therapeutics 预计2026年底前迎来首位参与者 初步数据料2027年下半年出炉
美股速递 · 07-14
Atrium Therapeutics 预计2026年底前迎来首位参与者 初步数据料2027年下半年出炉
上海乡村春游季带动消费2.6亿元，如何从“一时红”走向“一直火”？
澎湃新闻 · 07-08
上海乡村春游季带动消费2.6亿元，如何从“一时红”走向“一直火”？
RNA技术落地肾病研发 礼来(LLY)敲定19亿美元投资前沿生物管线
金吾财讯 · 06-03
RNA技术落地肾病研发 礼来(LLY)敲定19亿美元投资前沿生物管线
Atrium Therapeutics Q1净亏损1660万美元，BMS里程碑付款支撑收入
环球市场播报 · 05-15
Atrium Therapeutics Q1净亏损1660万美元，BMS里程碑付款支撑收入
Leerink Partners首予Atrium Therapeutics“跑赢大盘”评级，目标价25美元
美股速递 · 05-15
Leerink Partners首予Atrium Therapeutics“跑赢大盘”评级，目标价25美元
Atrium Therapeutics公布第一季度运营费用达3691.5万美元
美股速递 · 05-15
Atrium Therapeutics公布第一季度运营费用达3691.5万美元
港股异动 | 云顶新耀(01952)涨超3% 近期公布mRNA肿瘤疫苗EVM16首次人体数据 公司RNA平台进一步验证
智通财经 · 05-14
港股异动 | 云顶新耀(01952)涨超3% 近期公布mRNA肿瘤疫苗EVM16首次人体数据 公司RNA平台进一步验证
【券商聚焦】方正证券维持云顶新耀(01952)“强烈推荐”评级 指RNA平台进一步验证
金吾财讯 · 04-28
【券商聚焦】方正证券维持云顶新耀(01952)“强烈推荐”评级 指RNA平台进一步验证
Atrium Therapeutics获施贵宝心血管合作1500万美元里程碑付款
美股速递 · 04-23
Atrium Therapeutics获施贵宝心血管合作1500万美元里程碑付款
施贵宝将全面资助Atrium Therapeutics合作项目未来所有临床、注册及商业化活动
美股速递 · 04-23
施贵宝将全面资助Atrium Therapeutics合作项目未来所有临床、注册及商业化活动
Atrium Therapeutics 有望获得高达13.5亿美元研发里程碑付款、8.25亿美元商业里程碑付款及分层特许权使用费
美股速递 · 04-23
Atrium Therapeutics 有望获得高达13.5亿美元研发里程碑付款、8.25亿美元商业里程碑付款及分层特许权使用费
加载更多
公司概况
公司名称：
Atrium Therapeutics
所属市场：
NASDAQ
上市日期：
--
主营业务：
Atrium Therapeutics, Inc.于2025年9月30日根据特拉华州法律注册成立，是Avidity Biosciences, Inc.的直接全资子公司。该公司是一家生物制药公司，致力于开创向心脏输送RNA疗法的先河，旨在改变心肌病患者个人的护理标准。利用最初在Avidity开发的专有RNA递送平台，该公司将单克隆抗体的组织选择性与寡核苷酸的精确度相结合，以靶向以前无法药物治疗的疾病的遗传驱动因素。Atrium专注于解决影响全球数百万人的基因驱动心肌病，其开发管道包括针对与严重心脏病相关的特定基因驱动因素的项目。在稳健的临床前和积极的临床数据支持下，该公司定位于重新定义精准心脏病学中的治疗范式。
发行价格：
--
{"stockData":{"symbol":"RNA","market":"US","secType":"STK","nameCN":"Atrium Therapeutics","latestPrice":10.36,"timestamp":1789156800000,"preClose":10.35,"halted":0,"volume":247499,"hourTrading":{"tag":"盘后","latestPrice":10.2,"preClose":10.36,"latestTime":"19:30 EDT","volume":2089,"amount":21623.68,"timestamp":1789169408496,"change":-0.16,"changeRate":-0.015444,"amplitude":0.015444},"delay":0,"changeRate":0.0009661835748792065,"floatShares":15721000,"shares":17105600,"eps":-3.857827,"marketStatus":"休市中","change":0.01,"latestTime":"09-11 16:00:00 EDT","open":10.37,"high":10.41,"low":10.0041,"amount":2539725.095943,"amplitude":0.039217,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.857827,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1591934400000,"exchange":"NASDAQ","adjPreClose":10.35,"preHourTrading":{"tag":"盘前","latestPrice":10.51,"preClose":10.35,"latestTime":"08:20 EDT","volume":37,"amount":389.97001,"timestamp":1789129224777,"change":0.16,"changeRate":0.015459,"amplitude":0.004831},"postHourTrading":{"tag":"盘后","latestPrice":10.2,"preClose":10.36,"latestTime":"19:30 EDT","volume":2089,"amount":21623.68,"timestamp":1789169408496,"change":-0.16,"changeRate":-0.015444,"amplitude":0.015444},"volumeRatio":0.390705,"impliedVol":0.1535,"impliedVolPercentile":0.2174},"requestUrl":"/m/hq/s/RNA","defaultTab":"news","newsList":[{"id":"2665334895","title":"AI辅助设计出新型RNA转运蛋白","url":"https://stock-news.laohu8.com/highlight/detail?id=2665334895","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665334895?lang=zh_cn&edition=full","pubTime":"2026-09-08 07:06","pubTimestamp":1788822416,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["AIPO","QTOC","BK4139","VTHR","AGIX","BK4585","BK4505","ARTY","RNA","CHAT","IE0009354923.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665579163","title":"奥博与贝恩资本加持，RNA新贵Adarx递交美股上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2665579163","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665579163?lang=zh_cn&edition=full","pubTime":"2026-09-05 09:00","pubTimestamp":1788570049,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Adarx Pharmaceuticals Inc. 已在美国申请 IPO ，以协助资助开发一系列通过调节基因表达来治疗多种疾病的管道药物。文件显示，此类疗法能在不改变人体基因组或 DNA 的情况下，从基因层面解决疾病问题。去年 5 月，作为一项合作协议的一部分，制药商艾伯维向 Adarx 支付了 3.35 亿美元的首付款。如果 Adarx 完成在神经科学、免疫学和肿瘤学等疾病领域的药物里程碑节点，未来还有可能获得数十亿美元的后续付款。在本次发行前，奥博资本持有该公司 31% 的股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492426.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0009354923.USD","BK4588","BK4505","BK4585","IPOS","RNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662778926","title":"RNA疗法再迎突破！名古屋大学教授：新技术有望让药物作用时间更长","url":"https://stock-news.laohu8.com/highlight/detail?id=2662778926","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662778926?lang=zh_cn&edition=full","pubTime":"2026-08-27 13:27","pubTimestamp":1787808431,"startTime":"0","endTime":"0","summary":"RNA技术近日再迎突破！日本名古屋大学与富士胶片合作开发出一种新型脂质纳米颗粒，首次将带帽环状RNA高效递送入动物体内。现有的RNA疗法是让mRNA在体内短暂工作，制造抗原，激活免疫系统。这种RNA没有两端，同时引入了帽结构，因此更耐降解，能够在较长时间内持续产生蛋白质。新开发的脂质纳米颗粒FL0445-LNP的分支结构既可携带mRNA，也能携带更耐用的Cap-cirRNA治疗药物，同时在小鼠中施用时产生更低的炎症反应。静脉注射的LNP目前主要还是集中在肝脏。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"ifeng_tech","url":"https://tech.ifeng.com/c/8vvhwlGiEIp","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8vvhwlGiEIp","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"ifeng_tech","symbols":["BK4588","BK4139","BK4505","RNA","BK4585","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661424828","title":"日本名古屋大学与富士胶片公司合作开发出一种新型脂质纳米颗粒（LNP），首次将带帽的环状RNA（Cap-cirRNA）高效","url":"https://stock-news.laohu8.com/highlight/detail?id=2661424828","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661424828?lang=zh_cn&edition=full","pubTime":"2026-08-23 19:31","pubTimestamp":1787484701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","RNA","BK4588","BK4505","BK4139","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120034487","title":"Atrium Therapeutics 获资格：研发里程碑可高达13.5亿美元，商业里程碑达8.25亿美元，另享阶梯式版税","url":"https://stock-news.laohu8.com/highlight/detail?id=1120034487","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120034487?lang=zh_cn&edition=full","pubTime":"2026-08-13 20:03","pubTimestamp":1786622625,"startTime":"0","endTime":"0","summary":"Atrium Therapeutics 公司已具备获得里程碑付款的资格。具体来看，其研发里程碑款项总额最高可达13.5亿美元。与此同时，商业里程碑的潜在金额也相当可观，达到了8.25亿美元。此外，该公司还将有权收取阶梯式版税。这一系列激励措施，为这家生物技术公司注入了强劲的发展动力，也凸显了其候选药物的巨大商业潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306807586.USD","LU0882574055.USD","FTXH","LU1585245621.USD","LU0868494617.USD","IE0009355771.USD","BK4139","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4585","LU1093756325.SGD","LU1670710588.SGD","LU1571399168.USD","LU1670711123.USD","LU2133065610.SGD","LU0225771236.USD","LU0306806265.USD","LU1093756168.USD","LU1670711040.USD","IE0009354923.USD","BK4581","LU1718418525.SGD","BMY","LU2125154778.USD","LU1261432733.SGD","LU0225284248.USD","LU2242652126.USD","LU0096364046.USD","LU1883839398.USD","IE00BJJMRZ35.SGD","BK4534","LU1868836914.USD","LU1989771016.USD","IE0002141913.USD","LU1983299246.USD","BK4007","IE00B2B36J28.USD","BK4532","LU0237698245.USD","LU2125154935.USD","BK4505","LU1074936037.SGD","LU1291159041.SGD","LU1868837300.USD","LU0267386448.USD","LU0432979614.USD","LU1323610961.USD","IE00BSNM7G36.USD","LU1032466523.USD","LU1670710661.SGD","LU2242646821.SGD","IE00BFXG1179.USD","LU0321505868.SGD","LU1868836757.USD","LU0456855351.SGD","LU1430594728.SGD","LU0114720955.EUR","BK4559","LU1868837136.USD","LU2360032135.SGD","LU1868836591.USD","LU2596442595.SGD","RNA","LU0061475181.USD","BK4588","IHE","LU0985481810.HKD","LU0321505439.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176688754","title":"Atrium Therapeutics 获施贵宝1500万美元里程碑付款，源于全球心血管合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1176688754","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176688754?lang=zh_cn&edition=full","pubTime":"2026-08-13 20:02","pubTimestamp":1786622555,"startTime":"0","endTime":"0","summary":"Atrium Therapeutics 宣布，已从百时美施贵宝（Bristol Myers Squibb）获得一笔1500万美元的里程碑付款，这笔款项是基于双方此前达成的全球心血管疾病合作项目所产生的。此次付款标志着双方合作在研发或临床推进方面取得了关键性进展，进一步巩固了这两家公司在心血管治疗领域的战略联盟。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242652126.USD","LU2133065610.SGD","IE00BSNM7G36.USD","LU0061475181.USD","LU1291159041.SGD","LU1323610961.USD","LU0985481810.HKD","LU1430594728.SGD","LU1868837136.USD","LU1093756325.SGD","LU2125154778.USD","LU2242646821.SGD","BK4581","LU0882574055.USD","LU1670711123.USD","LU0321505439.SGD","LU1883839398.USD","IE00BFTCPJ56.SGD","LU1868836591.USD","LU0225284248.USD","IE00BJT1NW94.SGD","LU0456855351.SGD","IE00BFXG1179.USD","LU0432979614.USD","IE00B2B36J28.USD","LU0306807586.USD","LU2596442595.SGD","LU2360032135.SGD","IE0002141913.USD","RNA","IE0009354923.USD","BK4139","LU1868837300.USD","LU1074936037.SGD","BK4534","IE0009355771.USD","FTXH","IHE","LU0267386448.USD","LU0306806265.USD","LU1868836914.USD","LU0096364046.USD","LU1093756168.USD","LU1989771016.USD","BK4588","LU0868494617.USD","LU1032466523.USD","LU1261432733.SGD","BK4532","LU0225771236.USD","LU1670710661.SGD","LU1868836757.USD","LU2125154935.USD","BK4559","BK4585","LU0114720955.EUR","LU0237698245.USD","LU1585245621.USD","IE00BJJMRZ35.SGD","LU1670711040.USD","LU1718418525.SGD","LU1983299246.USD","BK4007","BK4505","LU1670710588.SGD","LU0321505868.SGD","BMY","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182050958","title":"Atrium Therapeutics（RNA）获施贵宝全额资助，未来开发与商业化活动全面启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1182050958","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182050958?lang=zh_cn&edition=full","pubTime":"2026-08-13 20:01","pubTimestamp":1786622485,"startTime":"0","endTime":"0","summary":"Atrium Therapeutics宣布，制药巨头Bristol Myers Squibb将为其后续所有开发及商业化活动提供全额资金支持。这一战略合作标志着Atrium Therapeutics在创新疗法领域迈出关键一步，同时彰显了施贵宝对RNA平台技术潜力的强烈信心。根据协议，施贵宝将承担从临床研究到市场推广的全链条成本，从而大幅降低Atrium Therapeutics的财务风险，并加速其候选药物的上市进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1074936037.SGD","LU0061475181.USD","BK4007","BK4532","IE00BFTCPJ56.SGD","LU1718418525.SGD","LU0096364046.USD","LU0456855351.SGD","LU2242646821.SGD","LU1868837136.USD","LU1093756325.SGD","BK4505","LU2360032135.SGD","BK4534","LU1291159041.SGD","FTXH","LU2133065610.SGD","LU1868836914.USD","LU1670710661.SGD","LU2125154935.USD","IE0002141913.USD","LU1989771016.USD","LU1585245621.USD","LU0868494617.USD","LU0225771236.USD","LU1983299246.USD","BK4581","LU1868837300.USD","LU2242652126.USD","LU0306807586.USD","LU0114720955.EUR","LU1032466523.USD","BK4559","LU0882574055.USD","LU0306806265.USD","LU0321505868.SGD","LU1868836591.USD","LU1670710588.SGD","LU1261432733.SGD","BK4139","IE00BFXG1179.USD","LU0432979614.USD","LU1868836757.USD","LU2596442595.SGD","IE00BSNM7G36.USD","LU0225284248.USD","LU0237698245.USD","IE0009355771.USD","LU1093756168.USD","LU1670711123.USD","LU1430594728.SGD","LU2125154778.USD","BK4585","IHE","LU0321505439.SGD","LU1323610961.USD","BMY","IE0009354923.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0985481810.HKD","LU1571399168.USD","LU1670711040.USD","RNA","LU1883839398.USD","IE00BJT1NW94.SGD","LU0267386448.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658980734","title":"石药集团(01093)：SYS 6037注射液(猴痘m RNA疫苗)在美国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2658980734","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658980734?lang=zh_cn&edition=full","pubTime":"2026-08-10 18:58","pubTimestamp":1786359500,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 公布，集团与中国科学院微生物研究所合作开发的预防用生物制品1类新药SYS 6037注射液已获得美国食品药品监督管理局批准，可在美国开展临床试验。猴痘由猴痘病毒引起，该病毒属于痘病毒科正痘病毒属。该产品有望成为具备市场竞争力的猴痘疫苗产品，进一步丰富集团m RNA疫苗创新产品管线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478098.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1813983027.USD","LU1152091168.USD","LU1951186391.HKD","LU2039709279.SGD","IE0009354923.USD","IBBQ","LU0314109678.HKD","IE00B5MMRT66.SGD","LU1993786604.SGD","IBBJ","LU1226288253.USD","HK0000165453.HKD","LU1960683339.HKD","RNA","LU0067412154.USD","IE00B031HY20.USD","LU1226287875.USD","LU0880133367.SGD","LU0072913022.USD","IE00BZ08YS42.EUR","LU1226288170.HKD","MDTX","LU0140636845.USD","BK1191","BK4505","LU1328277881.USD","BK1521","LU1152091754.HKD","LU0315179316.USD","LU0501845795.SGD","BK1515","BMED","BK4139","IE00BZ08YR35.GBP","BK4588","LU1226287792.SGD","SG9999004220.SGD","LU1807302812.USD","PSYK","IE00B543WZ88.USD","IE0008368742.USD","LU0326950275.SGD","IE00BZ08YT58.USD","BK4585","LU1226287529.USD","159646","LU1008478684.HKD","KURE","01093","IE0008369823.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165912646","title":"Atrium Therapeutics宣布FDA批准Atr 1072用于治疗Prkag2综合征的研究性新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1165912646","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165912646?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:32","pubTimestamp":1784025125,"startTime":"0","endTime":"0","summary":"Atrium Therapeutics公司宣布，其针对Prkag2综合征的治疗药物Atr 1072的研究性新药（IND）申请已获得美国食品药品监督管理局（FDA）的批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","RNA","IE0009354923.USD","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198034369","title":"Atrium Therapeutics 预计2026年底前迎来首位参与者 初步数据料2027年下半年出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=1198034369","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198034369?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:31","pubTimestamp":1784025081,"startTime":"0","endTime":"0","summary":"Atrium Therapeutics宣布，其临床试验预计将在2026年底前迎来首位参与者，而初步研究数据则有望在2027年下半年获得。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4585","BK4139","RNA","BK4588","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649957366","title":"上海乡村春游季带动消费2.6亿元，如何从“一时红”走向“一直火”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2649957366","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649957366?lang=zh_cn&edition=full","pubTime":"2026-07-08 12:15","pubTimestamp":1783484100,"startTime":"0","endTime":"0","summary":"比如今年市农业农村委和市文化和旅游局联合推出的上海乡村春游季，共接待游客949万人次，带动消费2.6亿元，取得了很好的成效。但要让乡村从“一时红”走向“一直火”，关键还要在内涵提升与长效机制的完善上下更多的功夫。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-07-08/doc-inihaicz1487621.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-07-08/doc-inihaicz1487621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BK4588","BK4505","IE0009354923.USD","RNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640188675","title":"RNA技术落地肾病研发 礼来(LLY)敲定19亿美元投资前沿生物管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2640188675","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640188675?lang=zh_cn&edition=full","pubTime":"2026-06-03 22:56","pubTimestamp":1780498602,"startTime":"0","endTime":"0","summary":"金吾财讯 | 总部位于波士顿的生物技术企业 Ascidian Therapeutics 周三披露合作协议，与礼来 敲定总额上限 19 亿美元的研发授权合作，依托前者 RNA 外显子编辑平台共同开发肾脏病创新药物。本次交易是礼来近期密集产业布局的又一落地项目。依托 GLP-1 减重产品带来的充沛现金流，药企持续重金布局 RNA、细胞治疗等前沿生物技术，通过外部合作补齐肾病管线，完善多元化新药储备。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/MjU4MmU0MDcxNDc2ODE0Nzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MjU4MmU0MDcxNDc2ODE0Nzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301131","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1035775433.USD","SGXZ31699556.SGD","LU1366192091.USD","IE00BKPKM429.USD","LU0471298694.HKD","LU0432979614.USD","SGXZ51526630.SGD","LU0683600562.USD","LU1548497426.USD","IE00B1BXHZ80.USD","IE0009354923.USD","LU0106261372.USD","LU0058720904.USD","LU1064131342.USD","LU0354030438.USD","BK4585","IE0005OL40V9.USD","LU1232071149.USD","LU0889565916.HKD","LU1023059063.AUD","LU2028103732.USD","LU1720051108.HKD","BK4534","LU0225283273.USD","LU0238689110.USD","LU2168564065.EUR","IE0004445239.USD","LU2756315664.SGD","LU1712237335.SGD","GB00BDT5M118.USD","LU0820562030.AUD","LU0640476718.USD","IE00BJT1NW94.SGD","LU2552382058.USD","LU2324357040.USD","LU1989771016.USD","LU0820561818.USD","SG9999001176.USD","ELIS","LU0203201768.USD","IE00B4R5TH58.HKD","LU2111349929.HKD","SG9999018865.SGD","BK4599","LU0708995401.HKD","LU0320765059.SGD","SG9999015986.USD","IE00BKDWB100.SGD","LU2471134523.USD","LU1093756325.SGD","LU0256863811.USD","LU0122379950.USD","LU0097036916.USD","LU1917777945.USD","LU0385154629.USD","LU1814569148.SGD","BK4505","LU0006306889.USD","BK4533","IE00B7KXQ091.USD","LU0256863902.USD","LU2213496289.HKD","LU2237443549.SGD","LU2361044949.HKD","LU0133085943.USD","LU1629891620.HKD","LU1623119135.USD","LU2468319806.SGD","BK4139","LU2552382215.SGD","LU2063271972.USD","LU0882574055.USD","LU0964807845.USD","LU2417539215.USD","LU0158827948.USD","SG9999015945.SGD","SG9999001176.SGD","LU1983299246.USD","LU2265009873.SGD","LU2746668974.SGD","LU1057294990.SGD","LU2023251221.USD","LU0079474960.USD","LU2237443622.USD","LU2491049909.HKD","LU0466842654.USD","LU1069344957.HKD","LU1868837136.USD","SGXZ57979304.SGD","LU2357305700.SGD","IE00B4JS1V06.HKD","SG9999014898.SGD","LU2750360641.GBP","LU0320765992.SGD","LU0266013472.USD","SG9999013999.USD","LU2461242641.AUD","LU2746668461.USD","LU0823434740.USD","LU2491050154.USD","LU2896262040.SGD","LU0316494557.USD","LU2168564222.USD","LU2023250330.USD","LU0786609619.USD","LU2756315318.SGD","LU0096364046.USD","LU0158827781.USD","LU2360106947.USD","LU0203202063.USD","SG9999014914.USD","IE00BK4W5M84.HKD","LU0820561909.HKD","LU1127390331.HKD","LU1868836914.USD","IE00BFTCPJ56.SGD","LU2237443465.HKD","IE00BN29S564.USD","LU0672654240.SGD","LU2168564149.EUR","LU0109394709.USD","SG9999015952.SGD","LU2462157665.USD","LU1988902786.USD","SG9999017495.SGD","RNA","LU2089984988.USD","SGXZ81514606.USD","LU0210536198.USD","LU2168563687.JPY","IE00BJLML261.HKD","LU2491050071.SGD","LU2106854487.HKD","LU2089284900.SGD","LU1093756168.USD","LLYX","LU0689472784.USD","LU1551013342.USD","LU2471134879.HKD","LU0094547139.USD","LU0289739699.SGD","LU1868836757.USD","LU0471298777.SGD","IE00BJJMRX11.SGD","IE00B775H168.HKD","LU2750360997.AUD","LU2236285917.USD","IE0009355771.USD","LU2552382132.HKD","BK4588","LU0061475181.USD","LU0109391861.USD","LU1868837300.USD","LU0456855351.SGD","LU0114720955.EUR","SG9999018857.SGD","LU1804176565.USD","LU2168564495.EUR","LU0823416689.USD","LU2237443978.SGD","SGXZ99366536.SGD","IE00BJJMRY28.SGD","LU1145028129.USD","IE00BFSS8Q28.SGD","LU0823434583.USD","IE00BFSS7M15.SGD","LU2087625088.SGD","LU2264538146.SGD","ELIL","LU0198837287.USD","IE0004445015.USD","LU2361045086.USD","LU0882574139.USD","LU2271345857.HKD","LU1868836591.USD","LU2089283258.USD","LU1323610961.USD","LU0323591593.USD","LU0943347566.SGD","LU0787776722.HKD","LU0353189763.USD","LLYZ","IE0002141913.USD","LU1280957306.USD","LU2237443895.HKD","IE00B2B36J28.USD","LU1974910355.USD","LU1061106388.HKD","LU2471134796.USD","LU0417517546.SGD","IE00BJJMRZ35.SGD","SG9999015978.USD","LU2602419157.SGD","LU0234572021.USD","LU2023250504.SGD","LU0354030511.USD","IE0001KFT4U8.USD","LLY","LU2361044865.SGD","SG9999014880.SGD","LU2237438978.USD","IE00B1XK9C88.USD","BK4007","LU1291159041.SGD","LU1551013425.SGD","LU1720051017.SGD","BK4516","IE00BK4W5L77.USD","SG9999014906.USD","LU2211815571.USD","LU2237443382.USD","LU2456880835.USD","LU0353189680.USD","LU2108987350.USD","LU2112291526.USD","LU2471134952.CNY","LU1267930730.SGD","LLII","BK4581","IE00BWXC8680.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635035758","title":"Atrium Therapeutics Q1净亏损1660万美元，BMS里程碑付款支撑收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2635035758","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635035758?lang=zh_cn&edition=full","pubTime":"2026-05-15 23:41","pubTimestamp":1778859660,"startTime":"0","endTime":"0","summary":" Atrium Therapeutics公布2026年第一季度财报。公司报告期内净亏损为1663万美元，合每股亏损0.97美元。作为对比，公司在作为Avidity Biosciences子公司期间的2025年同期净亏损为745万美元，合每股亏损0.44美元。需要说明的是，由于Atrium于2026年2月27日才完成从Avidity的分拆独立上市，本期财务数据不宜直接与历史同期进行比较。 Atrium于2月27日正式作为独立公司登陆纳斯达克。ATR 1072的IND申请预计于2026年下半年提交，ATR 1086的IND申请预计于2027年提交。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-15/doc-inhxyyie6355365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","BK4139","BK4588","BK4539","BK4505","RNA","LENZ","BMS","BK4585","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138398611","title":"Leerink Partners首予Atrium Therapeutics“跑赢大盘”评级，目标价25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1138398611","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138398611?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:08","pubTimestamp":1778839712,"startTime":"0","endTime":"0","summary":"Leerink Partners近日发布研究报告，首次覆盖生物技术公司Atrium Therapeutics，并给予“跑赢大盘”的评级，同时设定25美元的目标股价。\n这一评级反映了该机构对公司前景的积极看法。分析师认为，Atrium Therapeutics在相关治疗领域拥有发展潜力，其股价未来有上行空间。目标价的设定基于对该公司业务和财务状况的评估。\n市场将密切关注这一新评级对Atrium Therapeutics股票走势的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","RNA","BK4505","IE0009354923.USD","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119762769","title":"Atrium Therapeutics公布第一季度运营费用达3691.5万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119762769","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119762769?lang=zh_cn&edition=full","pubTime":"2026-05-15 05:18","pubTimestamp":1778793492,"startTime":"0","endTime":"0","summary":"生物制药公司Atrium Therapeutics Inc披露了其第一季度财务数据，显示该季度运营费用总计3691.5万美元。这一数字反映了公司在研发及日常运营方面的持续投入。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","BK4588","BK4585","BK4139","RNA","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635995057","title":"港股异动 | 云顶新耀(01952)涨超3% 近期公布mRNA肿瘤疫苗EVM16首次人体数据 公司RNA平台进一步验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2635995057","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635995057?lang=zh_cn&edition=full","pubTime":"2026-05-14 15:24","pubTimestamp":1778743450,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀涨超3%，截至发稿，涨3.48%，报31.48港元，成交额1.33亿港元。消息面上，云顶新耀近期宣布，公司在2026年美国癌症研究协会年会上公布自研mRNA个性化肿瘤治疗性疫苗EVM16单药治疗及联合PD-1抑制剂治疗晚期实体瘤的首次人体临床试验数据。方正证券指出，RNA平台中，现货型TAA mRNA疫苗EVM14实现中美新药临床IND双获批并完成首例患者入组给药；mRNA自体生成CAR-T项目EVM18完成非人灵长类动物概念验证并推进临床开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01952","BK4588","BK4505","BK1583","BK1574","IE0009354923.USD","159646","BK4139","RNA","VXUS","BK1161","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630932874","title":"【券商聚焦】方正证券维持云顶新耀(01952)“强烈推荐”评级 指RNA平台进一步验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2630932874","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630932874?lang=zh_cn&edition=full","pubTime":"2026-04-28 11:09","pubTimestamp":1777345757,"startTime":"0","endTime":"0","summary":"金吾财讯 | 方正证券发布研报指，云顶新耀 在AACR大会发布mRNA肿瘤疫苗EVM16首次人体数据，RNA平台进一步验证。商业化成果显著，2025年公司实现收入17.07亿元人民币，大幅增长141.51%。截至2025年12月31日，公司现金储备达27.31亿元人民币。盈利预测方面，方正证券预计2026-2028年公司销售收入分别为39.56/54.52/71.41亿元人民币，同比增长131.78%/37.83%/30.98%；归母净利润分别为2.53/6.65/11.47亿元人民币，维持“强烈推荐”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980112","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","RNA","601901"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105218816","title":"Atrium Therapeutics获施贵宝心血管合作1500万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1105218816","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105218816?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:04","pubTimestamp":1776945856,"startTime":"0","endTime":"0","summary":"Atrium Therapeutics宣布，根据其与施贵宝达成的全球心血管领域合作协议，公司已成功获得一笔1500万美元的里程碑付款。此次付款标志着双方合作取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836591.USD","BK4007","LU0225771236.USD","LU1670711040.USD","LU0868494617.USD","LU1074936037.SGD","LU1430594728.SGD","LU0456855351.SGD","IE00BFTCPJ56.SGD","BK4534","IE00BJT1NW94.SGD","RNA","LU1868836757.USD","BK4532","IE00BFXG1179.USD","LU1093756325.SGD","LU1571399168.USD","LU1989771016.USD","LU2360032135.SGD","LU2242652126.USD","BK4581","LU0432979614.USD","LU0985481810.HKD","BMY","IE0009355771.USD","LU0225284248.USD","LU0237698245.USD","IE00BSNM7G36.USD","LU0306806265.USD","IE0009354923.USD","LU2125154935.USD","BK4139","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0321505868.SGD","LU0096364046.USD","LU1718418525.SGD","LU1883839398.USD","LU2125154778.USD","LU0306807586.USD","LU1323610961.USD","BK4559","LU0321505439.SGD","LU1868837300.USD","LU1983299246.USD","LU1670710588.SGD","LU1585245621.USD","BK4588","LU1032466523.USD","LU1261432733.SGD","LU1670710661.SGD","LU1291159041.SGD","LU2242646821.SGD","LU2133065610.SGD","BK4585","LU1093756168.USD","LU1868836914.USD","LU0114720955.EUR","LU0882574055.USD","LU0061475181.USD","LU0267386448.USD","LU1868837136.USD","LU1670711123.USD","BK4505","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181426981","title":"施贵宝将全面资助Atrium Therapeutics合作项目未来所有临床、注册及商业化活动","url":"https://stock-news.laohu8.com/highlight/detail?id=1181426981","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181426981?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:03","pubTimestamp":1776945801,"startTime":"0","endTime":"0","summary":"根据最新合作协议条款，施贵宝（Bristol Myers Squibb）将承担与Atrium Therapeutics合作项目后续所有临床开发、注册申报及商业化活动的全部资金。这一安排标志着双方战略合作进入新阶段，由施贵宝主导推进项目全球化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BMY","LU1093756168.USD","LU1323610961.USD","LU1430594728.SGD","IE00BFXG1179.USD","LU0225771236.USD","LU0096364046.USD","IE0009355771.USD","LU1868836757.USD","LU1989771016.USD","IE0009354923.USD","LU0432979614.USD","LU1670711123.USD","LU1718418525.SGD","BK4588","LU2133065610.SGD","LU0267386448.USD","LU0114720955.EUR","LU0306806265.USD","LU0237698245.USD","LU1868837300.USD","IE0002141913.USD","LU1291159041.SGD","LU1670710661.SGD","IE00BFTCPJ56.SGD","LU0061475181.USD","LU1093756325.SGD","LU0321505439.SGD","LU2242652126.USD","BK4581","LU0321505868.SGD","IE00BSNM7G36.USD","IE00BJJMRZ35.SGD","LU0225284248.USD","BK4139","LU0985481810.HKD","LU2125154778.USD","LU2242646821.SGD","LU1670711040.USD","BK4559","LU1868836591.USD","LU1983299246.USD","LU1074936037.SGD","BK4585","LU1571399168.USD","LU1261432733.SGD","LU1670710588.SGD","LU1032466523.USD","LU0868494617.USD","LU1585245621.USD","LU2125154935.USD","LU1868837136.USD","BK4532","RNA","LU0306807586.USD","LU1868836914.USD","LU0882574055.USD","LU1883839398.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU2360032135.SGD","BK4007","LU0456855351.SGD","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123489677","title":"Atrium Therapeutics 有望获得高达13.5亿美元研发里程碑付款、8.25亿美元商业里程碑付款及分层特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1123489677","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123489677?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:02","pubTimestamp":1776945720,"startTime":"0","endTime":"0","summary":"生物技术公司Atrium Therapeutics Inc（RNA）宣布，其与制药巨头施贵宝（BMY）达成的合作协议中，包含丰厚的潜在财务回报。根据协议条款，Atrium有资格获得最高可达13.5亿美元的研发里程碑付款。\n此外，协议还涵盖了商业成功方面的激励。该公司有望进一步获得高达8.25亿美元的基于销售额的商业里程碑付款。除了这些一次性付款，合作协议还规定Atrium将获得基于产品净销售额的分层特许权使用费。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456855351.SGD","LU1430594728.SGD","LU0096364046.USD","IE0009355771.USD","LU0321505439.SGD","LU2133065610.SGD","BK4559","LU1323610961.USD","LU1571399168.USD","LU1032466523.USD","LU2242652126.USD","LU1670710588.SGD","LU1585245621.USD","LU0225284248.USD","LU1093756325.SGD","LU1261432733.SGD","IE00BFXG1179.USD","LU1868836757.USD","LU0114720955.EUR","LU0321505868.SGD","LU0432979614.USD","LU0868494617.USD","LU1983299246.USD","LU0882574055.USD","BK4581","LU0061475181.USD","LU2125154935.USD","IE00BFTCPJ56.SGD","BK4588","LU1093756168.USD","LU1868837300.USD","LU1670711123.USD","LU1291159041.SGD","BK4585","LU0237698245.USD","LU2242646821.SGD","IE0009354923.USD","LU0985481810.HKD","BK4534","IE00B2B36J28.USD","LU1670710661.SGD","BMY","LU0225771236.USD","LU1883839398.USD","RNA","BK4007","IE00BJJMRZ35.SGD","LU1074936037.SGD","IE00BSNM7G36.USD","LU1868836914.USD","LU1989771016.USD","LU1868837136.USD","BK4505","LU2360032135.SGD","LU0306806265.USD","IE0002141913.USD","LU0306807586.USD","LU0267386448.USD","BK4139","BK4532","LU1670711040.USD","LU1718418525.SGD","LU1868836591.USD","LU2125154778.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atriumtherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.2911},{"period":"1month","weight":-0.1565},{"period":"3month","weight":-0.1633},{"period":"6month","weight":-0.2473},{"period":"1year","weight":-0.425},{"period":"ytd","weight":-0.425}],"compareEarnings":[{"period":"1week","weight":-0.0198},{"period":"1month","weight":-0.0165},{"period":"3month","weight":0.0217},{"period":"6month","weight":0.1443},{"period":"1year","weight":0.1619},{"period":"ytd","weight":0.1113}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Atrium Therapeutics, Inc.于2025年9月30日根据特拉华州法律注册成立，是Avidity Biosciences, Inc.的直接全资子公司。该公司是一家生物制药公司，致力于开创向心脏输送RNA疗法的先河，旨在改变心肌病患者个人的护理标准。利用最初在Avidity开发的专有RNA递送平台，该公司将单克隆抗体的组织选择性与寡核苷酸的精确度相结合，以靶向以前无法药物治疗的疾病的遗传驱动因素。Atrium专注于解决影响全球数百万人的基因驱动心肌病，其开发管道包括针对与严重心脏病相关的特定基因驱动因素的项目。在稳健的临床前和积极的临床数据支持下，该公司定位于重新定义精准心脏病学中的治疗范式。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.025613},{"month":2,"riseRate":0.666667,"avgChangeRate":0.084173},{"month":3,"riseRate":0.4,"avgChangeRate":-0.00029},{"month":4,"riseRate":0.4,"avgChangeRate":-0.058331},{"month":5,"riseRate":0.4,"avgChangeRate":-0.018927},{"month":6,"riseRate":0.8,"avgChangeRate":0.113151},{"month":7,"riseRate":0.5,"avgChangeRate":0.027674},{"month":8,"riseRate":0.666667,"avgChangeRate":0.073003},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.048121},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.000506},{"month":11,"riseRate":0.666667,"avgChangeRate":0.096576},{"month":12,"riseRate":0.666667,"avgChangeRate":0.110632}],"exchange":"NASDAQ","name":"Atrium Therapeutics","nameEN":"Atrium Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Atrium Therapeutics(RNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Atrium Therapeutics(RNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Atrium Therapeutics,RNA,Atrium Therapeutics股票,Atrium Therapeutics股票老虎,Atrium Therapeutics股票老虎国际,Atrium Therapeutics行情,Atrium Therapeutics股票行情,Atrium Therapeutics股价,Atrium Therapeutics股市,Atrium Therapeutics股票价格,Atrium Therapeutics股票交易,Atrium Therapeutics股票购买,Atrium Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Atrium Therapeutics(RNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Atrium Therapeutics(RNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}